April 2012 Drug Information Update - Pharmacy Benefits ...

More documents

Recommendations

Info

Article link: http://www.ashp.org/DrugShortages/Current/Bulletin.aspx?id=38 Source: www.ashp.org Potassium Phosphate Injection March 27, 2012 Products Affected - Description Potassium phosphate injection, American Regent 3 mMol/mL, 5 mL vial (NDC 00517-2305-25) 3 mMol/mL, 15 mL vial (NDC 00517-2315-25) 3 mMol/mL, 50 mL vial (NDC 00517-2350-25) Potassium phosphate injection, Hospira 3 mMol/mL, 5 mL vial (NDC 00409-7296-01) 3 mMol/mL, 15 mL vial (NDC 00409-7295-01) Reason for the Shortage • Hospira was discontinuing their potassium phosphate injections but will be returning to market with the 5 mL and 15 mL sizes to help meet demand. • American Regent had temporarily suspended manufacture of most drug products including all potassium phosphate presentations in April, 2011. • American Regent resumed manufacturing in Shirley, New York in early-May, 2011. • American Regent has issued a statement that all lots of potassium phosphate may contain glass particles and filters must be used. Do not use if there are visible glass particles and filter all other product. Article link: http://www.ashp.org/DrugShortages/Current/Bulletin.aspx?id=709 Source: www.ashp.org Norepinephrine Injection March 27, 2012 Products Affected - Description Norepinephrine, 1 mg/mL, Bedford 4 mL vial, package of 10 (NDC 55390-0002-10) Norepinephrine, 1 mg/mL, Teva 4 mL vial, package of 10 (NDC 00703-1153-03) - temporarily discontinued Reason for the Shortage • Ben Venue voluntarily suspended all manufacturing and distribution in mid-November, 2011. Product will become available in stages as production resumes. • Bedford Laboratories has multiple products affected by this suspension of manufacturing. Availability of all products, including those not manufactured at Ben Venue, is updated as information changes on the Bedford Laboratories website. • Teva temporarily discontinued norepinephrine in June 2010. • Hospira had Levophed on shortage due to increased demand for the product. Hospira has increased production of Levophed to meet this demand. Article link: http://www.ashp.org/DrugShortages/Current/Bulletin.aspx?id=712 Source: www.ashp.org Mitomycin Injection March 27, 2012 Products Affected - Description Mitomycin Powder for Injection (Mannitol Formulation), Bedford 62
5 mg single dose vial, package of 1 (NDC 55390-0251-01) 20 mg single dose vial, package of 1 (NDC 55390-0252-01) 40 mg single dose vial, package of 1 (NDC 55390-0253-01) 5 mg Novaplus single dose vial, package of 1 (NDC 55390-0451-01) 20 mg Novaplus single dose vial, package of 1 (NDC 55390-0452-01) 40 mg Novaplus single dose vial, package of 1 (NDC 55390-0453-01) Mitomycin Powder for Injection (Mannitol Formulation), Accord 5 mg single dose vial (NDC 16729-0115-05) 20 mg single dose vial (NDC 16729-0108-11) Reason for the Shortage • Ben Venue voluntarily suspended all manufacturing and distribution in mid-November, 2011. Product will become available in stages as production resumes. • Bedford Laboratories has multiple products affected by this suspension of manufacturing. Availability of all products, including those not manufactured at Ben Venue, is updated as information changes on the Bedford Laboratories website. • Accord states the reason for the shortage is increased demand. Article link: http://www.ashp.org/DrugShortages/Current/Bulletin.aspx?id=433 Source: www.ashp.org Epinephrine Injection March 27, 2012 Products Affected - Description Epinephrine injection, 1 mg/mL, American Regent 1 mL ampule, sulfite-free, package of 25 (NDC 00517-1071-25) Reason for the Shortage • American Regent had temporarily suspended manufacture of most drug products in April, 2011. • American Regent resumed manufacturing in Shirley, New York in early-May, 2011. Article link: http://www.ashp.org/DrugShortages/Current/Bulletin.aspx?id=685 Source: www.ashp.org Bupivacaine with epinephrine injection March 27, 2012 Products Affected - Description Bupivacaine 0.25% with epinephrine Bupivacaine 0.25% with epinephrine 1:200,000 injection, Hospira 10 mL vial, preservative-free (NDC 00409-9042-01) 50 mL vial, multi-dose (NDC 00409-9043-01) 30 mL vial, preservative-free (NDC 00409-9042-17) Marcaine 0.25% (with epinephrine 1:200,000) injection, Hospira 10 mL vial, preservative-free (NDC 00409-1746-10) 30 mL vial, preservative-free (NDC 00409-1746-30) 50 mL vial, multi-dose (NDC 00409-1752-50) Sensorcaine 0.25% (with epinephrine 1:200,000), APP 10 mL vial, preservative-free (NDC 63323-0468-17) 30 mL vial, preservative-free (NDC 63323-0468-37) 50 mL vial, multi-dose (NDC 63323-0461-57) Bupivacaine 0.5% with epinephrine Bupivacaine 0.5% with epinephrine 1:200,000 injection, Hospira 63
Page 1 and 2:
April 2012 Drug Information Update
Page 3 and 4:
First-Time Generics GENERIC DRUG NA
Page 5 and 6:
GENERAL ANESTHETICS, INJECTABLE MID
Page 7 and 8:
Gruenhaupt, Mark R.Ph. Argus Health
Page 9 and 10:
Statin Drugs - Drug Safety Communic
Page 11 and 12: Vytorin (ezetimibe/simvastatin) Tab
Page 13 and 14: low blood sugar (hypoglycemia) in p
Page 15 and 16: Some women with depression who beco
Page 17 and 18: Survival increased for all groups o
Page 19 and 20: finding that it also may reduce the
Page 21 and 22: Syringes (2 mL size), Rx only. NDC
Page 23 and 24: Patheon Pharmaceuticals Inc., Cinci
Page 25 and 26: 50-ct. bottles (NDC 0067-6238-50);
Page 27 and 28: PRODUCT (Class II) 1) Ventolin HFA
Page 29 and 30: Lot #: 0693, Exp: 10/2012 RECALLING
Page 31 and 32: 24 (Display case UPC# 3030045074923
Page 33 and 34: CODE Lot # 139961 RECALLING FIRM/MA
Page 35 and 36: Reason for the Shortage • Teva co
Page 37 and 38: Reason for the Shortage • Ben Ven
Page 39 and 40: Products Affected - Description Gan
Page 41 and 42: 37.5 mg/25 mg, 1000 count (NDC 0078
Page 43 and 44: Acyclovir tablets, Major 400 tablet
Page 45 and 46: 500 mg, 100 count (NDC 63304-0726-0
Page 47 and 48: 750 mg tablets, 100 count (NDC 1013
Page 49 and 50: • Bedford Laboratories has multip
Page 51 and 52: Daunorubicin Hydrochloride Injectio
Page 53 and 54: Ciprofloxacin Immediate-Release Tab
Page 55 and 56: • APP had tobramycin 40 mg/mL pre
Page 57 and 58: • Ben Venue voluntarily suspended
Page 59 and 60: 50 mg/mL, 10 mL vial, package of 10
Page 61: 2 mL vial, preservative-free (NDC 6
Page 65 and 66: 20 mL glass ampule, sterile pack (N
Page 67 and 68: 2 mL iSecure syringe (NDC 00406-112
Page 69 and 70: Lidocaine 0.5% Xylocaine 0.5% injec
Page 71 and 72: • Teva discontinued all ciproflox
Page 73 and 74: Nicardipine hydrochloride injection
Page 75 and 76: Article link: http://www.ashp.org/D
Page 77 and 78: • Apotex had metformin products u
Page 79: • Covis purchased all rights to F
show all

April 2012 Drug Information Update - Pharmacy Benefits ...

Create successful ePaper yourself

Delete template?

Save as template?